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Purpose: We aimed to determine whether handgrip strength (HGS) improves type 2 diabetes (T2D) risk 
prediction beyond conventional risk factors. 
Design: Handgrip strength was assessed at baseline in 776 individuals aged 60-72 years without a history 
of T2D in a prospective cohort. Handgrip strength was normalised to account for the effect of body 
weight. Hazard ratios (HRs) (95% confidence intervals [CI]) and measures of risk discrimination for T2D 
and reclassification [net reclassification improvement (NRI), integrated discrimination index (IDI)] were 
assessed. Results: During 18.1 years median follow-up, 59 T2D events were recorded. The HR (95% CI) 
for T2D adjusted for conventional risk factors was 0.49 (0.31-0.80) per 1 standard deviation higher 
normalized HGS and was 0.54 (0.31-0.95) and 0.53 (0.29-0.97) on adjustment for risk factors in the 
DESIR and KORA S4/F4 prediction models, respectively. Adding normalized HGS to these risk scores 
was associated with improved risk prediction as measured by differences in -2 log likelihood, NRI and 
IDI. Sex-specific HRs and risk prediction findings using sensitive measures suggested the overall results 
were driven by those in women. Conclusion: Adding measurements of HGS to conventional risk factors 
might improve T2D risk assessment, especially in women. Further evaluation is needed in larger studies. 
 









• Handgrip strength (HGS) is independently associated with reduced risk of type 2 diabetes 
(T2D), but its utility in classifying or predicting T2D risk has not been explored.  
• In this prospective cohort study of older Caucasian men and women, adding measurements 
of HGS to conventional risk factors improved T2D risk assessment, especially in women.  
• Assessment of HGS is simple and inexpensive and could prove a valuable clinical tool in 









Though several established risk factors such as older age, obesity, family history of type 2 diabetes 
(T2D), physical inactivity, smoking, and excessive alcohol consumption explain a large proportion of the 
risk of T2D, identification of individuals at increased risk of T2D remains a difficult undertaking. Some 
of these conventional risk factors are sometimes not present in individuals identified to have developed 
T2D. Hence, there is a need for further identification of easily measurable factors that could have 
predictive relevance for T2D. Handgrip strength (HGS), used as a measure of muscular strength, has 
emerged as a strong risk indicator for adverse vascular outcomes as well as mortality.(1, 2) Until recently, 
there was diverging evidence on the link between HGS and the risk of T2D. Based on a pooled analysis of 
10 prospective cohort studies,(3) we have demonstrated that increased HGS is independently associated 
with reduced risk of T2D. Although the independent association of HGS with risk of T2D is suggestive of 
its usefulness in risk prediction, such information is insufficient for making judgements in clinical 
practice about its potential utility in classifying or predicting T2D risk in individuals.(4) Various 
measures which have been proposed for evaluating the predictive accuracy of a risk marker include risk 
discrimination and reclassification.(5)  Given that the assessment of HGS is inexpensive and quick to do 
and with the absence of any evidence about its potential value in T2D risk prediction strategies, its 
potential utility for T2D risk assessment warrants detailed investigation. Using a population-based sample 
of participants free from T2D at baseline, we report the extent to which HGS measurements could 












Materials and methods 
Study design and population 
We conducted this study in accordance with STROBE (STrengthening the Reporting of OBservational 
studies in Epidemiology) guidelines for reporting observational studies in epidemiology (Supplementary 
Material 1). We used primary data from the Kuopio Ischemic Heart Disease (KIHD) study, a population-
based prospective cohort study which was designed in Kuopio, Finland, to investigate emerging risk 
factors for vascular disease and other related chronic diseases.(6) Details of the study design and 
recruitment have been reported previously.(1) In the initial KIHD study, participants comprised a 
representative sample of men recruited from the city of Kuopio and its surrounding rural communities in 
eastern Finland. Re-examinations were conducted for these participants underwent at 4 years, 11 years 
and 20 years after study entry. Women were invited to join the original study during the 11-year 
examinations, and this was the cohort that was employed for the current analysis. A total of 2,358 
participants (1007 men and 1351 women) aged 53 to 74 years were initially recruited for this cohort.(7) 
Of the 2,072 participants found to be potentially eligible, 193 did not agree to participate, 66 did not 
respond to the invitation and 39 declined to provide informed consent, which left 1,774 participants who 
had baseline examinations conducted from March 1998 to December 2001.(7) A subset of 875 randomly 
selected eligible participants had HGS measurements at the 11-year re-examination (baseline examination 
for this cohort). Of the 1,774 participants, we excluded 143 participants with a pre-existing history of 
diabetes. This was followed by further exclusion of 840 participants who did not have data on HGS 
measurements and 15 participants with missing covariate data. The current analysis is based on 776 men 
and women without a history of T2D at baseline and with complete information on HGS, relevant 







of Kuopio and Kuopio University Hospital, Kuopio, Finland (License number 143/97) approved the study 
research protocol. Written informed consent was obtained from all participants and all study procedures 
were conducted according to the Declaration of Helsinki. 
 
Assessment of HGS and relevant risk markers 
The dominant hand of each study participant was used in the measurement of HGS using a hand 
dynamometer (in kPa; Martin-Balloon-Vigorimeter; Gebrüder Martin, Tuttlingen, Germany). Two 
measurements were taken, and their mean value was used for analysis; there was a one-minute resting gap 
between both measurements. The dynamometers were calibrated at the beginning of each test. To account 
for the influence of body weight and to normalize the data, absolute values of HGS were allometrically 
scaled (normalized HGS = HGS/body weight2/3).(8, 9) All results were multiplied by 100 for easier 
readability.(9) Study procedures including blood sample collection, measurement of blood-based markers, 
physical measurements, and assessment of lifestyle characteristics have been described previously.(7, 10) 
Self-reported questionnaires were used to assess baseline socio-demographic and lifestyle characteristics, 
existing medical conditions and use of medications.(11) The energy expenditure of physical activity was 
assessed from a validated 12-month leisure-time physical activity questionnaire.(12)  
 
Ascertainment of incident T2D  
All incident T2D cases that occurred from study entry to 2018 were included. An incident T2D case was 
defined as a fasting plasma glucose (FPG) ≥ 7.0 mmol/l, a 2 h glucose tolerance test plasma glucose ≥ 
11.1 mmol/l, or use of glucose-lowering medication according to self-report at re-examination and by 
record linkage to the national hospital discharge registry and to the Social Insurance Institution of Finland 









Descriptive analyses were used to summarise baseline characteristics of participants; means (standard 
deviation, SD) or medians (interquartile range, IQR) for continuous variables and percentages for 
categorical variables. To examine the association of baseline levels of HGS with risk of T2D, hazard 
ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox proportional hazard models 
after confirming no substantial departure from the assumptions of proportionality of hazards.(13) 
Normalized HGS was modeled per SD increase. Adjustment for covariates were based on four models: 
(Model 1) age and sex; (Model 2) model 1 plus high-density lipoprotein cholesterol (HDL-C), systolic 
blood pressure (SBP), smoking status, physical activity, family history of diabetes, and FPG; (Model 3) 
including component variables in the the 9 year Data from the Epidemiological Study on the Insulin 
Resistance Syndrome (DESIR) risk score (i.e. smoking, parental history of diabetes, hypertension, and 
waist circumference) (14) employed for the risk prediction analyses; and (Model 4) including risk factors 
in the Cooperative Health Research in the Region of Augsburg (KORA) S4/F4 model (i.e. age, sex, BMI, 
smoking, parental diabetes, hypertension and glucose) which was developed to specifically predict the 
risk of T2D in older subjects (15, 16). As we accounted for the influence of body weight during 
computation of our exposure (normalized HGS), BMI was replaced with waist circumference to avoid 
overfitting of the model. The selection of covariates in model 2 was based on their established role as risk 
factors for T2D, evidence from previous research,(3, 17, 18) or their potential as confounders based on 
known associations with T2D and observed associations with the exposure using the available data. Given 
the few events in the study (n=59), only a few covariates were chosen at a time in each model to avoid 
overfitting. We evaluated if the overall association between HGS and T2D was modified by sex using 







confounders in both genders. 
To assess whether adding information on HGS to conventional T2D risk factors is associated with 
improvement in prediction of T2D risk, we employed distinct statistical approaches. First the 
improvement in risk discrimination resulting from adding HGS information to a model containing the 
DESIR variables(14)  was quantified using Harrell’s C-index.(19) The C-index is appropriate for time-to-
event data and provides the probability that the model correctly predicts the order of failure of randomly 
selected pairs of individuals. A C-index of 1.0 indicates perfect prediction of the order of failure (in this 
case T2D), whereas a C-index of 0.5 is achieved purely by chance. We employed the individual variables 
included in the risk score rather than published formulas in the original study because these are based on 
different populations and time points and outcomes may be slightly different. Furthermore, using 
individual variables rather than published scores is conservative because models with individual variables 
usually predict outcomes better than the scores, and it is more difficult for new variables to improve risk 
prediction.(20) The 95% CIs for C-indices and their changes were derived from jackknife standard error. 
Comparison of the C-index for models including and not including information on HGS was performed 
according to the methodology of DeLong(21) and with the Stata command “somersd”. Second, we 
calculated the continuous net reclassification improvement (NRI) (22), a category-free version of the NRI 
(which does not depend on the arbitrary choice of categories and determines whether risk increases to any 
extent for cases under a new model compared to the old or reference model, and similarly whether risk 
decreases to any degree for non-cases). Finally, we calculated the integrated discrimination improvement 
(IDI), which integrates the NRI over all possible cut-offs and mathematically corresponds to the 
difference in discrimination slopes of the 2 models in comparison.(5)  
 







detecting differences.(23, 24) To avoid discarding potential biomarkers that can be used in risk prediction, 
sensitive risk discrimination methods such as the -2 log likelihood test have been recommended.(23, 24)  
Therefore, in addition to Harrel’s C-index which has disadvantages such as being based on ranks only, not 
being able to assess calibration and findings may not be of clinical importance,(25) we tested differences 
in the -2 log likelihood of prediction models with and without inclusion of HGS. Sex-specific analyses 
were also conducted. Given that the KORA S4/F4 model(15, 16) seemed to perform better in the KIHD 
cohort, we also explored model improvement on addition of information on HGS.  
 
Exploration of the data suggested a missing completely at random mechanism, hence we did not 
anticipate a complete-case analysis would have produced biased estimates. However, given that about 
50% of the original participants did not have data on HGS measurements, we conducted multiple 
imputation by chained equations (MICE) to handle potential selection bias originating from missingness. 
The imputation model included all model covariates as well as T2D outcome status. Given the 
computational time required, 10 imputations were computed. Cox regression analyses were run across the 
10 imputed datasets and the pooled estimates were reported. All statistical analyses were conducted using 
Stata version MP 16 (Stata Corp, College Station, Texas). 
 
Results 
Handgrip strength and risk of T2D 
The overall mean (SD) age of study participants at study entry was 69 (3) years and 47.2% were males. 
The mean (SD) values of normalized HGS and weight were 0.49 (0.23) kPa/kg2/3 and 75.2 (12.9) kg 
respectively (Table 1). Except for baseline levels of HGS, weight, BMI, waist circumference and FPG, 







participants who did and did not develop T2D. Individuals who developed T2D had lower HGS and 
higher levels of weight, BMI, waist circumference and FPG. Baseline characteristics by sex are presented 
in Supplementary Material 3. 
 
During a median (interquartile range, IQR) follow-up of 18.1 (12.1-19.2) years, a total of 59 T2D cases 
(annual rate 4.92/1,000 person-years at risk; 95% CI: 3.81-6.35) were recorded. The age- and sex-
adjusted HR for T2D per 1 SD increase in normalized HGS was 0.38 (95% CI: 0.24-0.57) which was 
minimally attenuated to 0.49 (95% CI: 0.31-0.80) on further adjustment for established risk factors and 
other potential confounders (HDL-C, SBP, smoking status, physical activity, family history of diabetes, 
and FPG) (Table 2). In a third model that adjusted for risk factors in the DESIR risk score, there was still 
evidence of an association 0.54 (95% CI: 0.31-0.95), which was minimally attenuated to 0.51 (95% CI: 
0.28-0.94) on additional adjustment for FPG. In the fourth model which adjusted for risk factors in the 
KORA S4/F4 score, the HR for T2D per 1 SD increase in normalized HGS was 0.53 (95% CI: 0.29-0.97). 
 
In sex-specific analyses, normalized HGS was strongly and inversely associated with T2D in women, 
whereas there was no evidence of an association in men (Table 2). Data was imputed for 1,631 
participants and the imputed results were broadly similar to those obtained using observed values 
(Supplementary Material 4). 
 
Handgrip strength and T2D risk prediction 
Results of risk prediction analyses are presented in Table 3. A T2D risk prediction model (DESIR) 
containing established risk factors yielded a C-index of 0.6596 (95% CI: 0.5904, 0.7288). After addition 







marginal significant increase of 0.0383 (-0.0047, 0.0814; p=0.08). On investigating differences in the -2 
log likelihood of the DESIR score, the -2 log likelihood was significantly improved on addition of 
normalized HGS to the DESIR score (p for comparison=0.01). The continuous NRI and IDI were 23.33% 
(95% CI -27.17, 73.83; p=0.37) and 0.0062 (95% CI -0.0007, 0.0132; p=0.08) respectively. On addition 
of normalized HGS to the KORA S4/F4 score, the C-index change was (0.0182; p=0.17), difference in -2 
log likelihood (p=0.01), NRI (58.44%; p=<.001) and IDI (0.0062; p<.001). The results were stronger in 
women compared to men (Tables 3-4).  
 
Discussion 
Our findings of an inverse and independent association between baseline normalized HGS and T2D risk 
generally concur with previous population-based cohort studies as well as our recent pooled analysis of 
10 studies on the topic.(3) Our sex-specific analyses suggested evidence of effect modification; there was 
a strong inverse association in women, whereas there was no evidence of an association in men. Given the 
low number of events in men and women, these findings need to be interpreted with caution. Indeed, in 
our meta-analysis of existing studies, we found no evidence of effect modification by sex.(3) With 
regards to the potential utility of HGS measurements for T2D risk assessment, the addition of information 
on normalized HGS to two different risk models containing traditional risk factors for T2D was 
associated with an improvement in the discrimination of T2D risk using measures such as NRI, IDI and 
difference in -2 log likelihood, a more sensitive measure when evaluating the added predictive value of a 









The mechanistic pathways underlying the association between increased HGS and reduced T2D risk have 
been extensively discussed in our pooled analysis of 10 studies evaluating the association between HGS 
and T2D.(3) Briefly, factors proposed to mediate this effect include reduction in higher muscle mass, 
incidence of weight gain, abdominal adiposity, insulin resistance, and inflammation;(26) decrease in 
visceral fat deposition and improvement in insulin sensitivity and glycaemic control;(27) as well as 
frailty.(28) Apart from the low number of events, the differences in the results  for men and women may 
partly be explained by marked differences in body composition (eg, lean mass, muscle strength, percent 
body fat). 
 
The current findings of a strong independent association between HGS and T2D risk and the added 
prognostic value of HGS on top of established risk factors may have several implications for the 
development of T2D prevention strategies. Assessment of HGS is simple, inexpensive and does not 
require very skilled expertise and facilities/resources. Handgrip strength is assessed quantitatively using a 
dynamometer and this involves the subject squeezing its handles with maximum isometric effort and 
maintaining this for 5 seconds. The use of HGS in risk assessment can easily be adopted in any clinical 
setting, whether general or specialized. However, given the low number of events in our analyses and 
some of the marginally significant findings, we propose larger studies to replicate these findings and 
robustly assess if information on HGS might aid in the early identification of people at high risk of future 
T2D. Furthermore, there is a need to identify further preventive strategies for T2D. Though it is quite well 
established that physical activity can prevent or delay T2D,(29, 30) resistance training should be 
promoted as a population-wide approach for the prevention of T2D, given its effectiveness in increasing 









Several strengths of this evaluation deserve mention and they include the novelty, being the first study to 
assess the potential utility of HGS measurements in T2D risk prediction; use of a well-characterised 
cohort of men and women who were nationally representative; employment of the MartinVigorimeter in 
assessment of HGS, given its high reliability and accuracy when assessing grip strength in older 
patients;(31) the use of allometric scaling to normalize HGS data; the long and complete follow-up of 
study participants; the use of sensitive measures such as the -2 log likelihood in our formal risk prediction 
analyses; the use of a category-free NRI, which has the advantage of not requiring pre-specified 
categories and does not lose information due to categorization;(25) and finally the use of multiple 
imputation methods, which showed that the results of our complete-case analyses were not biased. 
Limitations of the current study which were mostly inherent included: (i) inability to generalize the 
findings to other age groups and ethnicities; (ii) the inability to correct for regression dilution because of 
absence of repeat measurements of HGS, hence the observed associations could be underestimated; (iii) 
the low number of incident cases of T2D, which precluded detailed sex-specific analyses and 
establishment of cut-offs for men and women; and (iv) the potential for residual confounding due to other 
unknown or unmeasured covariates such as frailty and andropause. 
 
Conclusion 
In a predominantly older Caucasian population, we have confirmed previous findings of an inverse and 
independent association between HGS and T2D risk, which appears to be modified by sex. These new 
data suggest adding measurements of HGS on top of conventional risk factors improves T2D risk 







low number of events in the current KIHD cohort, further evaluation is needed in studies with larger 
samples, other age groups and populations. 
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TABLE 1 Baseline participant characteristics, overall and by incident T2D status 
 
 Overall (N=776) 
Mean (SD), median 
(IQR) or n (%) 
Developed T2D (N=59) 
Mean (SD), median 
(IQR) or n (%) 
No T2D (N=717) 
Mean (SD), median 
(IQR) or n (%) 
p-value 
Normalized handgrip strength (kPa/kg2/3) 0.49 (0.23) 0.39 (0.13) 0.49 (0.24) .001 
     
Questionnaire/Prevalent conditions     
Age at survey (years) 69 (3) 69 (3) 69 (3) .86 
Males 366 (47.2) 24 (40.7) 342 (47.7) .30 
Family history of diabetes 258 (33.3) 21 (35.6) 237 (33.1) .69 
Current smokers 74 (9.5) 6 (10.2) 68 (9.5) .98 
History of hypertension 347 (44.7) 27 (45.8) 320 (44.6) .87 
     
Physical measurements     
Weight (kg) 75.2 (12.9) 81.9 (12.5) 74.7 (12.8) <.001 
Height (cm) 164 (9) 163 (8) 164 (9) .38 
BMI (kg/m2) 27.9 (4.3) 30.8 (5.1) 27.6 (4.2) <.001 
Waist circumference (cm) 92.4 (11.7) 98.3 (11.3) 92.0 (11.6) <.001 
SBP (mmHg) 139 (18) 140 (21) 138 (17) .52 
DBP (mmHg) 80 (9) 82 (11) 80 (9) .12 
Energy expenditure of total LTPA 
(kcal/day) 
386 (232-680) 407 (258-702) 382 (231-677) .93 
     
Blood-based markers     
Total cholesterol (mmol/l) 5.48 (0.93) 5.31 (0.91) 5.50 (0.93) .14 
HDL-C (mmol/l) 1.25 (0.31) 1.19 (0.27) 1.25 (0.31) .11 
FPG (mmol/l) 4.90 (0.52) 5.45 (0.58) 4.86 (0.48) <.001 
 
BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; IQR, interquartile 





TABLE 2 Overall and sex-specific association of normalized handgrip strength with type 2 diabetes 
 Overall 
(776 participants, 59 cases) 
Men 
(366 participants, 24 cases) 
Women 
(410 participants, 35 cases) 
p-value for 
interaction 
Models HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value  
Model 1 0.38 (0.24-0.57) <.001 0.66 (0.32-1.37) .26 0.29 (0.17-0.49) <.001 .08 
Model 2 0.49 (0.31-0.80) .004 1.04 (0.45-2.42) .92 0.37 (0.21-0.67) .001 .04 
Model 3 0.54 (0.31-0.95) .03 0.57 (0.22-1.46) .24 0.56 (0.28-1.13) .10 N/A 
Model 4 0.53 (0.29-0.97) .04 1.07 (0.43-2.67) .89 0.41 (0.20-0.81) .01 .06 
 
CI, confidence interval; HR, hazard ratio; HRs are reported per standard deviation increase 
Model 1: Adjusted for age and sex (not adjusted for sex in the sex-specific analysis) 
Model 2: Model 1 plus high-density lipoprotein cholesterol, systolic blood pressure, smoking status, physical activity, family 
history of diabetes and fasting plasma glucose 
Model 3: Sex, smoking, parental history of diabetes, hypertension and waist circumference (adjusted for smoking, hypertension 
and waist circumference in men and parental history of diabetes, hypertension and waist circumference in women) 






TABLE 3 Risk discrimination and reclassification upon addition of normalized handgrip strength to the 
DESIR T2D risk prediction model containing conventional risk factors 
 
Discrimination Overall  Men Women 
C-index (95% CI): conventional risk factors 0.6596 (0.5904 to 0.7288) 0.5508 (0.4303 to 0.6713) 0.7441 (0.6697 to 0.8185) 
C-index (95% CI): conventional risk factors plus 
HGS 
0.6979 (0.6261 to 0.7698) 0.6326 (0.5284 to 0.7368) 0.7588 (0.6804 to 0.8371) 
C-index change (95% CI) 0.0383 (-0.0047 to 0.0814) 0.08181 (-0.0429 to 0.2065) 0.0147 (-0.0167 to 0.0460) 
p-value .08 .20 .36 
p-value for difference in -2 log likelihood .01 .25 .03 
    
Reclassification    
Continuous Net reclassification index (95% CI) 33.26% (-18.09 to 84.60) 55.20% (-44.08 to 154.49) 15.09% (-49.11 to 79.29) 
p-value  .20 .28 .65 
    Integrated discrimination index (95% CI) 0.0122 (0.0002 to 0.0242) 0.0075 (-0.008 to 0.0178) 0.0160 (-0.0001 to 0.0321) 
p-value  .05 .16 .05 
 
The model with conventional risk factors included sex, smoking, parental history of diabetes, hypertension and waist circumference 
(smoking, hypertension and waist circumference for men and parental history of diabetes, hypertension and waist circumference 
for women) 








TABLE 4 Risk discrimination and reclassification upon addition of normalized handgrip strength to the 
KORA S4/F4 T2D risk prediction model containing conventional risk factors 
 
Discrimination Overall  Men Women 
C-index (95% CI): conventional risk factors 0.8052 (0.7462 to 0.8642) 0.7255 (0.6146 to 0.8365) 0.8634 (0.8060 to 0.9207) 
C-index (95% CI): conventional risk factors plus 
HGS 
0.8234 (0.7646 to 0.8821) 0.7780 (0.6791 to 0.8770) 0.8758 (0.8206 to 0.9310) 
C-index change (95% CI) 0.0182 (-0.0079 to 0.0443) 0.0525 (-0.0059 to 0.1108) 0.0124 (-0.0046 to 0.0295) 
p-value .17 .08 .15 
p-value for difference in -2 log likelihood .01 .33 .04 
    
Reclassification    
Continuous Net reclassification index (95% CI) 58.44% (35.16 to 81.72) 55.58% (-41.47 to 152.64) 59.90% (28.18 to 91.63) 
p-value  <.001 .26 <.001 
    Integrated discrimination index (95% CI) 0.1965 (0.1403 to 0.2527) 0.0125 (-0.0024 to 0.0275) 0.3236 (0.2350 to 0.4122) 
p-value  <0.001 .10 <.001 
 
The model with conventional risk factors included age, sex, waist circumference, parental history of diabetes, smoking and 
hypertension (sex was not included in the separate models for men and women) 
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Supplementary Material 1: STROBE 2007 Statement—Checklist of items that should be included in 





Reported on page 
# 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title 
or the abstract 
Page 1 
(b) Provide in the abstract an informative and balanced summary of 
what was done and what was found 
Page 2 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation 
being reported 
Page 3 
Objectives 3 State specific objectives, including any prespecified hypotheses Page 3 
Methods  
Study design 4 Present key elements of study design early in the paper Study design and 
population 
 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
Study design and 
population 
 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection 
of participants. Describe methods of follow-up 
Study design and 
population 
 
(b) For matched studies, give matching criteria and number of exposed 
and unexposed 
Study design and 
population 
 
Variables 7 Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, if applicable 
Assessment of 
HGS and relevant 
risk markers; 
Ascertainment of 
incident T2D  
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability of 
assessment methods if there is more than one group 
Assessment of 






Bias 9 Describe any efforts to address potential sources of bias Statistical analysis 
 
Study size 10 Explain how the study size was arrived at Statistical analysis 
 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why 
Statistical analysis 
 




(b) Describe any methods used to examine subgroups and interactions Statistical analysis 
 
(c) Explain how missing data were addressed Not applicable 
(d) If applicable, explain how loss to follow-up was addressed Not applicable 




Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included 
in the study, completing follow-up, and analysed 
Supplementary 
Material 2 
  (b) Give reasons for non-participation at each stage Supplementary 
Material 2 
  (c) Consider use of a flow diagram Supplementary 
Material 2 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, 
social) and information on exposures and potential confounders 
Results; Table 1  
  (b) Indicate number of participants with missing data for each variable 
of interest 
 
  (c) Summarise follow-up time (eg, average and total amount) Results 
Outcome data 15* Report numbers of outcome events or summary measures over time Results 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 




  (b) Report category boundaries when continuous variables were 
categorized 
Results; Tables 2-4 
  (c) If relevant, consider translating estimates of relative risk into 
absolute risk for a meaningful time period 
 
Other analyses 17 Report other analyses done—eg analyses of subgroups and 




   
Key results 18 Summarise key results with reference to study objectives Discussion 
Limitations    
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and 
other relevant evidence 
Discussion 
Generalisability 21 Discuss the generalisability (external validity) of the study results Discussion 
Other information 
   
Funding 22 Give the source of funding and the role of the funders for the present 
study and, if applicable, for the original study on which the present 






Supplementary Material 2: Participant flow 
Remaining participants
n = 1774
(920 women and 854 men)
Data on handgrip strength, risk factors 
and outcomes were available for 776 
participants 
(410 women and 366 men)
Baseline examination
Years 1998−2001
Invited, n = 2358
(1351 women and 1007 men)
- Death 72
- Severe illness 135
- Migrated 20
- Unknown address 5
- Premenopausal 54
Eligible, n = 2072
(1173 women and 899 men)
- Refused 193
- No contact 66 
- Other reasons 39
- 840 with no HGS 
data












Supplementary Material 3: Baseline participant characteristics, overall and by sex 
 Overall (N=776) 
Mean (SD), median 
(IQR) or n (%) 
Women (N=410) 
Mean (SD), median 
(IQR) or n (%) 
Men (N=366) 
Mean (SD), median 
(IQR) or n (%) 
Normalized handgrip strength (kPa/kg2/3) 0.49 (0.23) 0.54 (0.28) 0.42 (0.14) 
    
Questionnaire/Prevalent conditions    
Age at survey (years) 69 (3) 69 (3) 68 (3) 
Family history of diabetes 258 (33.3) 139 (33.9) 119 (32.5) 
Current smokers 74 (9.5) 18 (4.4) 56 (15.3) 
History of hypertension 347 (44.7) 201 (49.0) 146 (39.9) 
    
Physical measurements    
Weight (kg) 75.2 (12.9) 71.2 (12.8) 79.7 (11.5) 
Height (cm) 164 (9) 158 (5) 171 (6) 
BMI (kg/m2) 27.9 (4.3) 28.6 (4.9) 27.1 (3.4) 
Waist circumference (cm) 92.4 (11.7) 88.5 (11.6) 96.8 (10.0) 
SBP (mmHg) 139 (18) 140 (18) 137 (18) 
DBP (mmHg) 80 (9) 79 (9) 81 (9) 
Energy expenditure of total LTPA 
(kcal/day) 
386 (232-680) 376 (230-630) 393 (242-693) 
    
Blood-based markers    
Total cholesterol (mmol/l) 5.48 (0.93) 5.72 (0.94) 5.21 (0.85) 
HDL-C (mmol/l) 1.25 (0.31) 1.35 (0.32) 1.14 (0.26) 
FPG (mmol/l) 4.90 (0.52) 4.83 (0.48) 4.98 (0.55) 
 
BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol;  







Supplementary Material 4: Imputed results for the overall and sex-specific association of normalized 
handgrip strength with type 2 diabetes 
 Overall 
(1,631 participants, 114 
cases) 
Men 
(774 participants, 56 
cases) 
Women 
(857 participants, 58 cases) 
Models HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
Model 1 0.47 (0.35-0.62) <.001 0.66 (0.42-
1.05) 
.08 0.37 (0.26-0.53) <.001 
Model 2 0.58 (0.42-0.82) .002 0.86 (0.49-
1.51) 
.60 0.46 (0.30-0.71) .001 
Model 3 0.67 (0.45-1.00) .05 0.77 (0.43-
1.38) 
.36 0.64 (0.39-1.05) .08 
Model 4 0.65 (0.41-1.05) .08 0.78 (0.40-
1.52) 
.45 0.59 (0.32-1.10) .09 
 
CI, confidence interval; HR, hazard ratio; HRs are reported per standard deviation increase 
Model 1: Adjusted for age and sex (not adjusted for sex in the sex-specific analysis) 
Model 2: Model 1 plus high-density lipoprotein cholesterol, systolic blood pressure, smoking status, physical activity, family 
history of diabetes and fasting plasma glucose 
Model 3: Sex, smoking, parental history of diabetes, hypertension and waist circumference (adjusted for smoking, hypertension 
and waist circumference in men and parental history of diabetes, hypertension and waist circumference in women) 
Model 4: age, sex, waist circumference, smoking, parental diabetes, hypertension and glucose (not adjusted for sex in the sex-
specific analyses) 
 
 
 
 
 
 
 
